Director/PDMR Shareholding

Released : 10 Apr 2017 17:21

RNS Number : 1189C
Amryt Pharma PLC
10 April 2017
 

10 April 2017

AIM: AMYT

ESM: AYP

 

Amryt Pharma plc

("Amryt" or the "Company")

Director Share Purchase

 

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announces that it has been notified that Markus Ziener, Non-Executive Director, has purchased 100,000 ordinary shares of 1p each ("Ordinary Shares") at a price of 21.5p per Ordinary Share.

 

Following this transaction, Mr Ziener holds 100,000 Ordinary Shares, representing 0.05% of the Company's issued share capital (excluding treasury shares).  Mr Ziener is the Executive Managing Director of Software AG Stiftung, a 20.9% shareholder in Amryt.

 

 

Full details as required under the Market Abuse Regulation are set out below.

 

Notification of Transactions of Directors / Persons Discharging Managerial Responsibility and Connected Persons

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Markus Ziener

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

 

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Amryt Pharma plc

b)

 

LEI

 

 

213800BOS8WAJO2BEQ38

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Ordinary shares of 1p each in Amryt Pharma plc

 

GB00BDD1LS57

b)

 

Nature of the transaction

 

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

21.5p

100,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

- Price

 

 

 

 

N/A (single transaction)

 

 

 

 

e)

 

Date of the transaction

 

 

30/03/17

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

 

Enquiries:

Amryt Pharma plc

C/o KTZ Communications

Joe Wiley, CEO

Rory Nealon, CFO/COO


Shore Capital

+44 (0) 20 7408 4090

Nomad and Joint Broker


Bidhi Bhoma, Edward Mansfield


Davy

+353 (1) 679 6363

ESM Adviser and Joint Broker


John Frain, Anthony Farrell


Stifel

+44 (0) 20 7710 7600

Joint Broker


Jonathan Senior, Ben Maddison


KTZ Communications

+44 (0) 20 3178 6378

Katie Tzouliadis, Emma Pearson


 

About Amryt Pharma plc - see www.amrytpharma.com

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

 

The Company recently acquired an exclusive licence to sell LOJUXTA (lomitapide), across the EU and other territories including the Middle East, North Africa, Turkey and Israel. LOJUXTA is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. 

 

Amryt's product, AP101 (Episalvan), received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to develop AP101 (Episalvan) as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. The Company recently received regulatory clarity from the FDA and the EMA regarding  its Phase 3 study of AP101 (Episalvan) in EB, which has been granted US and EU orphan drug designation, and the first study site was initiated at the end of March 2017. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

 

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. AP102 was recently granted orphan designation in the US in acromegaly by the FDA.

 

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKKDDABKDCQD